Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Compare The Efficacy And Safety of Lenalidomide (Revlimid) Versus Placebo In Subjects With Transufsion-Dependent Anemia Due to IPSS Low Or Imtermidate-1 Risk Myelodysplastic Syndromes Without Deletion 5Q(31) And Unresponsive Or Refractory To Erthropoiesis-Stimulating Agents
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms MDS-005
- Sponsors Celgene Corporation
- 01 Sep 2022 Data from 3 studies (DS-003, MDS-004, and MDS-005) assessing impact of lenalidomide treatment on overall survival in patients with lower-risk myelodysplastic syndromes, published in the Clinical Lymphoma, Myeloma & Leukemia.
- 23 Jul 2018 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Results (n=198) assessing relationship between somatic gene mutations and overall survival, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology